This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: CTRCD

December 2020

Sacubitril-valsartan benefits in cancer therapy-related cardiac dysfunction

BJC Staff

Abstract

The patients who developed cardiotoxicity were treated with beta blockers (carvedilol), angiotensin-converting enzyme inhibitors (enalapril) or angiotensin receptor blockers (valsartan), aldosterone antagonists (eplerenone), digitalis and diuretics (furosemide), as needed. When patients remained symptomatic and met the PARADIGM-HF inclusion criteria, sacubitril/valsartan was started instead of enalapril or valsartan. Results showed that sacubitril/valsartan therapy produced an improvement in ventricular remodelling, diastolic dysfunction, and on symptoms, reflected in the New York Heart Association class and the six-minute walk test. The auth

| Full text

April 2017 Br J Cardiol 2017;24:56-8 Online First

News from the 9th BSH day for revalidation and training

Dr Simon Beggs

Abstract

Cardio-oncology and obstetrics Many cancer therapies are cardiotoxic, and as cancer survival has improved over recent decades so the number of patients living to develop cardiovascular complications of these therapies has risen. A recent position statement by the European Society of Cardiology stresses that “the cured cancer patient of today…[is at risk of becoming]…the heart failure patient of tomorrow”1 and management of these patients increasingly involves a cardiologist. In a highly educational presentation, Dr Zaheer Yousef (University Hospital of Wales, Cardiff) addressed the management of left ventricular systolic dysfunction (

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now